|
Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793-800, 2007. |
|
|
Singh RP, Deep G, Blouin M-J, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28: 2567-74, 2007. |
|
|
Schernhammer ES, Tworoger SS, Eliassen AH, MIssmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocrine-Related Cancer 14:721-732, 2007. |
|
|
Raina K, Blouin M-J, Singh RP, Majeed N, Deep G, Varghese L, Glod¨¦ LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.?Cancer Res 67:11083-91, 2007. |
|
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12, 2007. |
|
|
Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2164-5, 2007. |
|
|
Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier AL. Milk consumption and the prepubertal somatotropic axis. Nutr J 6: 28, 2007.? |
|
|
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer?97: 98-104, 2007. |
|
|
Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak M, Ma J, Fuchs CS. Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev?16: 2101-9, 2007. |
|
|
Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res?67: 7923-8, 2007. |
|
|
Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ. Hypoxia-inducible factor-1 alpha gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer. Prostate?67: 1354-91, 2007. |
|
|
Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev?16: 1691-5, 2007. |
|
|
Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr?86: 820S-2S, 2007. |
|
|
De Bono JS, Attard G, Adjei A,Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res?13: 3611-6, 2007. |
|
|
Levitt RJ, Zhao Y, Blouin M-J, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett?255: 300-6, 2007. |
|
|
Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev?16: 929-33, 2007. |
|
|
McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol?109: 933-41, 2007. |
|
|
Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev?16: 844-6, 2007. |
|
|
Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutl¨¦e F, Pollak MN, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepihtelial neolplasia. Cancer Epidemiol Biomarkers Prev?16: 716-22, 2007. |
|
|
Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab?92: 1319-25, 2007. |
|
|
Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res?9: R18, 2007. |
|
|
Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res?174: 49-53, 2007. |
|
|
Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and C-peptide levels and risk of breast cancer among predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev?16: 161-4, 2007. |
|
|
Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging?28: 135-42, 2007. |
|
|
Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene?26: 1811-9, 2007. |
?